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Abstract
Background: Chronic heart failure is an important cause for morbidity and mortality in adults with congenital heart disease
(ACHD). While NT-proBNP is an established biomarker for heart failure of non-congenital origin, its value in ACHD has
limitations. Asymmetrical dimethylarginine (ADMA) correlates with disease severity and independently predicts adverse
clinical events in heart failure of non-congenital origin. Its role in ACHD has not been investigated.
Methods: In 102 patients ADMA and NT-proBNP were measured and related to NYHA class, systemic ventricular function
and parameters of cardiopulmonary exercise testing.
Results: In contrast to NT-proBNP ADMA differentiated between NYHA classes I-III. Both, ADMA and NT-proBNP showed a
good correlation with parameters of cardiopulmonary exercise testing with comparable receiver-operating characteristic
curves for identifying patients with severely limited cardiopulmonary exercise capacity.
Conclusion: ADMA seems to be a better biomarker than NT-proBNP for the assessment of NYHA class and as a good as NT-
proBNP for the estimation of maximum exercise capacity in adults with congenital heart disease. Its use in clinical routine
should be evaluated.
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Introduction
Chronic heart failure is an important cause for morbidity and
mortality in adults with congenital heart disease (ACHD) [1].
However, heart failure symptoms especially in the early stages of
the disease do not correlate with objective measures like systemic
ventricular function or parameters of cardiopulmonary exercise
testing [2,3]. The rather rare incidence of individual malforma-
tions, the abnormal anatomy and the complex physiology make
assessment of cardiac function difficult [4]. Therefore, the
prevalence of heart failure in these patients is underappreciated
[5,6]. A simple investigation such as a blood test to quantitatively
or qualitatively evaluate subclinical/early stages of heart failure or
predict those at risk of deterioration would be clinically valuable
[4]. B-type natriuretic peptide (BNP) and N-terminal pro-BNP
(NT-proBNP) are established tools for diagnosis and management
of heart failure due to acquired heart disease [7]. Unfortunately,
the clinical use of those markers is hampered in adults with
congenital heart disease by several limitations. Hence the diagnosis
and treatment monitoring is frequently based on cardiopulmonary
exercise testing [4] [5,8,9]. Asymmetrical dimethylarginine
(ADMA) has emerged as a new biomarker in heart failure of
non-congenital origin. Observations in laboratory animals sug-
gested that plasma ADMA levels are increased in experimental
heart failure [10]. The association between high ADMA levels and
heart failure in humans has been first described almost ten years
ago [11]. Recent studies proved, that ADMA correlates with
disease severity and independently predicts adverse clinical events
in heart failure [12–14]. Further, ADMA correlates with
parameters of impaired exercise capacity and reduced ventilatory
capacity [13]. Its role in ACHD has not been studied. Therefore,
the aim of this cross-sectional study in adults with congenital heart
disease was to elucidate the potential diagnostic value of ADMA.
Materials and Methods
The patients were recruited during a routine outpatient visit at
the Adult Congenital Heart Disease Clinic of the Hannover
Medical School. All patients in whom a venous blood sampling
was feasible were eligible for this study. The study was approved
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Germany. All patients gave written informed consent.
A clinical workup including medical history, physical examina-
tion, 12-lead electrocardiography, transthoracic echocardiography
and cardiopulmonary exercise testing was performed.
The severity of the congenital heart defect was graded
according to complexity as proposed by recent guidelines [15].
The patients were further classified according to their symptoms of
heart failure using the New York Heart Association (NYHA)
functional classification. The NYHA classification is based on the
symptoms of the patients and the limitations to normal physical
activities [7].
Laboratory methods
Blood samples for measurement of plasma ADMA and NT-
proBNP, and routine chemistry were drawn. Blood samples were
immediately cooled on ice, centrifuged at 1,500 g and 4uC for
10 min. Supernatants were stored in 1 ml aliquots at 280uC until
further use.
Plasma concentrations of ADMA were measured applying a
liquid chromatography-mass spectrometry method described
elsewhere [16]. The lower limit of quantification for ADMA was
0.15 mmol/l and the inter-batch precision and accuracy was better
than 6%.
All other measurements were done with routine laboratory tests
using certified assay methods.
Echocardiography
A standard 2D-Doppler transthoracic echocardiogram was
performed according to the recommendations for the assessment
of ventricular function and valvular heart disease issued by the
American Society of Echocardiography [17]. Systemic ventricular
systolic function was assessed qualitatively (i.e. normal, moderately
or severely impaired). Valvular function was quantified by color
and continuous-wave Doppler flow.
Cardiopulmonary exercise studies
Cardiopulmonaryexercise studies wereperformed ona bicycle in
sitting position, starting with 25 W, increasing further 25 W every
2 min. All patients exercised to the end of their tolerance. A 12-lead
ECG was recorded throughout the exercise test to determine heart
rate and increase in heart rate. Systolic blood pressure and increase
in systolic blood pressure, as well as work rate (W/kg) were
measured. Ventilation, oxygen uptake (VO2), and carbon dioxide
production (VCO2), were measured continuously by a breath-by-
breath method. Subjects breathed through a fitted mask and a hot-
wire anemometer (Oxycon Delta, Ja ¨ger, Hoechberg, Germany)
measuring inspired and expired flow continuously.
Statistical analysis
We used SPSS 15.0 and R for statistical analysis. Continuous
data are presented as mean 6 standard deviation. Categorical
data are presented as counts and proportions. Patient demo-
graphic and clinical characteristics were summarized as means 6
standard deviation. Comparisons between groups were done using
unpaired Student’s t test for continuous and Mann-Whitney-U test
for categorical variables. If more than two groups were compared
one-way ANOVA or Kruskal-Wallis-test were used depending on
the distribution of the data. For correlation Pearson’s correlation
coefficient was calculated. The significance level was set at p,0.05
and was two-sided.
For the parameters of cardiopulmonary exercise testing cut off
values representing patients with limitations of their cardiopulmo-
nary exercise capacity were defined: peak oxygen uptake (peak
VO2) ,20 ml/min/kg, ventilatory equivalent for carbon dioxide
(EQCO2).34, ventilatory equivalent for oxygen (EQO2).34,
oxygen pulse for female ,9 ml/heartbeat, for male ,12 ml/
heartbeat. For further analysis a group of patients that was severely
affected was defined. These patients had a peakVO2,20 ml/min/
kg or an EQCO2.34 or a combination of both. Univariate logistic
regression analysis was performed. Parameters with a p value,0.1
were included into a multivariate logistic regression analysis.
Receiver-operating characteristic curves (ROC curve) for these
parameters were drawn and the areas under the curves calculated.
Results
One hundred and two patients were enrolled in our cross-
sectional study. Due to incomplete data sets 5 patients were
excluded. Because of the small number (n=3) of patients with
NYHA IV these were also excluded. Hence, the final analysis is
based on 94 patients. Table 1 and 2 show the clinical
characteristics of the study population. Cardiopulmonary exercise
testing was performed in 72 patients.
Clinical characteristics possibly influencing ADMA and
NT-proBNP levels
Renal function assessed by the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) equation [18] did not
differ between patients in NYHA I, NYHA II and NYHA III
(Table 3). Arterial hypertension was equally prevalent in all three
groups. Only 1 patient was diabetic.














single ventricle 15 (16)
Systemic ventricular function
normal 52 (55.3)
moderately impaired 35 (37.2)
severely impaired 7 (7.4)
NYHA class
NYHA I 56 (59.6)
NYHA II 21 (22.3)
NYHA III 17 (18.1)
Data are expressed as mean6SD or as counts (percentage).
doi:10.1371/journal.pone.0033795.t001
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ADMAdidnotreachastatisticallysignificantdifferenceinpatients
with severe ventricular dysfunction (0.5060.14 mmol/l) compared to
patients with moderate dysfunction (0.4760.08 mmol/l, p=0.36)
and normal ventricular function (0.4660.07 mmol/l, p=0.23). NT-
proBNP was elevated in severe ventricular dysfunction compared to
moderately impaired ventricular function (115661540 pg/ml vs.
3796466 pg/ml, p,0.001) and normal ventricular function
(1426177 pg/ml, p,0.001) and also between the later two
(p=0.037).
NYHA class
ADMA differentiated between NYHA classes: NYHA I
(0.4460.06 mmol/l) to NYHA II (0.4860.08 mmol/l, p=0.04),
and NYHA III (0.5460.10 mmol/l, p,0.001) and between
NYHA II and III (p=0.02). (Figure 1) NT-proBNP was
significantly lower in patients with NYHA I (1296202 pg/ml)
compared to patients with NYHA II (4326517 pg/ml, p=0.026)
and NYHA III (71961035 pg/ml, p,0.001), but not between the
later two (p=0.97). (Figure 1)
Cardiopulmonary exercise testing
Peak VO2 was significantly higher in patients in NYHA I
(28.867.6 ml/min/kg) vs. patients in NYHA II (23.364.5 ml/
min/kg, p=0.007) and patients in NYHA III (14.165.2 ml/min/
kg, p,0.001) and also in comparison between NYHA II and
NYHA III (p=0.001). When grouped according to ventricular
function patients with a normal function had a significantly higher
peak VO2 (28.567.6 ml/min/kg) compared to patients with a
moderate (21.568.2 ml/min/kg, p=0.001) or severe impairment
of their ventricular function (21.068.4 ml/min/kg, p=0.023).
There was no significant difference between the later two
(p=0.879).
ADMA was elevated in patients with limited cardiopulmonary
exercise capacity compared to their peers. Significant differences
were observed for peak VO2 (p=0.004), EQCO2 (p=0.002) and
EQO2 (p=0.005). There was not a statistically significant
difference for oxygen pulse (p=0.088) (Table 4).
Uni-variate logistic regression analysis regarding the ability to
identify patients with severely limited cardiopulmonary exercise
capacity (defined as peakVO2,20 ml/min/kg or an EQCO2.34
or a combination of both) revealed four parameters with a p
value,0.1: age, ADMA, cystatin C and NT-proBNP (Table 5).
The areas under the receiver-operating characteristic (ROC)
curves for identifying patients with severely limited cardiopulmo-
nary exercise capacity were 0.663 for age, 0.593 for cystatin C,
0.766 for ADMA, and 0.827 for NT-proBNP (Figure 2). Optimal
cut off values for ADMA and NT-proBNP were 0.502 mmol/l and
250 pg/ml respectively. Multivariate logistic regression analysis
revealed that only ADMA (p logreg=0.0081) and NT-proBNP (p
logreg=0.0087) showed a significant influence.
Discussion
In this study, ADMA was for the first time evaluated in adults
with congenital heart disease. It was significantly elevated in
ACHD that bear the hallmarks of heart failure. This holds true for
subjective measures of heart failure like NYHA class as well as
objective measures like cardiopulmonary exercise parameters.
Especially, ADMA was superior to NT-proBNP in differentiating
NYHA classes.
In patients with chronic heart failure of non-congenital origin a
correlation of elevated ADMA concentrations with impaired
exercise capacity was recently reported. In a study of 113 patients
elevated ADMA concentrations were associated with lower peak
VO2, increased VE/VCO2 slope, and shorter exercise duration on
the treadmill [13]. This is in accordance with our results that
ADMA was elevated in ACHD with limited cardiopulmonary
exercise capacity compared to their peers. ADMA further was able
to distinguish patients with an especially impaired exercise
capacity demonstrated by lower peak VO2 and increased EQCO2.
The area under the receiver-operating characteristic curve is
0.766. The importance of this finding is demonstrated by the fact
that poor exercise capacity identifies ACHD at risk for
hospitalization or death [2]. Peak VO2 predicted hospitalization
or death and was related to the frequency and duration of
hospitalization in a large cohort of ACHD [2]. Further, an
increased ventilatory response to exercise is also a powerful
predictor of mortality in ACHD [19]. NT-proBNP displayed also
a significant difference between patients with a peak VO2 or
EQCO2 under or over the cut off value. This is in contrast to the
findings of Larsson et al. that the ability of elevated BNP or NT-
proBNP levels in ACHD with a systemic right ventricle or a single
ventricle to identify those with impaired exercise capacity was
weak [4].
In our study, ADMA increased in correlation with NYHA class.
Usui et al. demonstrated that ADMA correlated with NYHA class
in chronic heart failure of non-congenital origin [20]. Further,
Norozi et al. showed that there is an incremental risk to exhibit
heart failure with rising NYHA class in ACHD [3]. The odds ratio
for patients in NYHA II compared to patients in NYHA I was 3.4
and for patients in NYHA III 11.6 [3]. This provides us with
further evidence that ADMA can act as a surrogate marker for
heart failure in ACHD. In contrast, NT-proBNP was not able to
differentiate between the NYHA classes in our study.
Table 2. Type of congenital heart defect.
Congenital heart defect Number (%)
TGA after Mustard and CCTGA 11 (11.7)
Tetralogy of Fallot 12 (12.8)
Coarctation of the aorta 11 (11.7)
Atrial or ventricular septal defect 10 (10.6)
Atrioventricular septal defect 6 (6.4)
Marfan syndrome 8 (8.5)
Congenital aortic or pulmonary valve stenosis 13 (13.8)
Single ventricle physiology 13 (13.8)
Miscellaneous 10 (10.6)
TGA=transposition of the great arteries; CCTGA=congenital corrected
transposition of the great arteries; miscellaneous: Ebstein’s anomaly, subaortic
stenosis, pulmonary atresia.
doi:10.1371/journal.pone.0033795.t002
Table 3. Clinical characteristics according to NYHA class.
NYHA I NYHA II NYHA III p
GFR ml/min 116614 116611 107618 n.s.
arterial hypertension No. (%) 7 (14%) 2 (11%) 3 (21%) n.s.
GFR=glomerular filtration rate calculated with the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) equation; n.s.=non-significant.
doi:10.1371/journal.pone.0033795.t003
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and ADMA levels an increase of ADMA levels in parallel with
worsening ventricular function was observed. This was however
not statistical significant. A larger sample size would probably lead
to statistically significant results. Moreover, echocardiographic
assessment of ventricular function is difficult in these patients [4].
In our study there was a good correlation between ventricular
function and NT-proBNP concentrations. This is in contrast to the
finding of Larsson and colleagues [4]. In their study, subjects with
moderately or severely impaired ventricular function did have
elevated BNP/NT-proBNP concentrations as compared with
subjects with normal or only mildly impaired ventricular function,
but the association was weak and only statistically significant when
BNP and NT-proBNP data were combined [4]. It appeared that
BNP/NT-proBNP had especially poor discrimination in evaluat-
ing differences between patients with no or mild ventricular
impairment [4], which suggests a limited ability of BNP/NT-
proBNP to diagnose heart failure at the initial stages.
Although the very nature of this clinical analysis is prohibitive for
making pathophysiological assumptions, several published papers
pointedto potential links between ADMA and heart failure. ADMA
is formed when protein-incorporated arginine is methylated by the
enzymes protein arginine methyltransferases (PRMT) [12]. Nitric
oxide is formed from the amino acid arginine by the enzyme nitric
oxide synthase (NOS) [12]. ADMA is the most potent endogenous
nitric oxide synthase (NOS) inhibitor [21,22] and acts by competing
with arginine for NOS binding [12].
Nitric oxide (NO) is involved in the modulation of all regulatory
steps of excitation-contraction coupling in the heart [23] and leads
to cGMP-mediated relaxation and vasodilation [12]. Elevated
ADMA levels have been found in a variety of cardiac diseases [12].
Further, systemic ADMA infusions lead to a decrease in cardiac
output in healthy volunteers [24]. Furthermore, ADMA infusion
has been shown to impair relaxation of coronary arteries, induce
myocardial remodelling, deteriorate cardiac function, and cause
myocardial ischaemia [12]. Endogenous NO synthase inhibitors,
Figure 1. ADMA and NT-proBNP in comparison between NYHA classes. (* p,0.05, ** p,0.001)
doi:10.1371/journal.pone.0033795.g001
Table 4. ADMA and NT-proBNP in patients with limitations of their cardiopulmonary exercise capacity.
ADMA in mmol/l NT-proBNP in pg/ml
,cut off . cut off p ,cut off . cut off p
peak VO2 in ml/min/kg 0.5060.08 0.4460.06 0.004 6446999 2036371 ,0.001
EQCO2 0.4560.06 0.5360.09 0.002 2326408 86861258 0.005
EQO2 0.4460.06 0.5060.08 0.005 1876312 6206979 0.005
Oxygen pulse in ml/beat 0.4860.10 0.4560.05 0.088 6016927 1516209 ,0.001
doi:10.1371/journal.pone.0033795.t004
Table 5. Results of univariate logistic regression analysis for
different parameters regarding their ability to identify patients
with severely limited cardiopulmonary exercise capacity.
Odds ratio 95% confidence intevall p logreg
age 1.0678 1.0069 1.1324 0.0285
body mass index 0.9025 0.7874 1.0345 0.1409
AST 0.9694 0.9159 1.026 0.2826
cystatin C 269.5165 0.8392 86552.8027 0.0574
NT-proBNP (log.) 2.8467 1.6394 4.9432 0.0002
ADMA 5533225.887 368.0284 83190842073 0.0016
sex 0.4286 0.1528 1.2024 0.1075
AST=aspartat aminotransferase.
doi:10.1371/journal.pone.0033795.t005
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is frequently encountered in heart failure [26]. Oechslin et al. have
demonstrated that endothelial dysfunction is evident in adults with
cyanotic congenital heart disease caused possibly by a reduced
basal bioavailability of NO [27]. In summary, the unfavourable
actions of ADMA are primarily the result of diminished NO
availability, resulting in disturbed vasodilatation and anti-throm-
botic, anti-inflammatory, and anti-apoptotic actions that overall
might induce cardiac dysfunction [12]. Therefore, it is reasonable
to assume that ADMA is involved in the dysfunction of various
components of the cardiovascular system. That is why it probably
better reflects the various pathophysiological changes involved in
adults with congenital heart disease. In contrast, the BNP gene in
cardiomyocytes is activated in response to increased myocardial
wall stress due to volume- or pressure-overload states [28]. This
results in the production of an intracellular precursor propeptide
and after further processing in the release of the biologically inert
aminoterminal fragment (NT-proBNP) and the biologically active
BNP [28]. The half-life of NT-proBNP is longer than that of BNP,
making it a better target for diagnostic blood testing. But in adults
with congenital heart disease increased myocardial wall stress due
to volume- or pressure-overload states is not always the
mechanism of heart failure. For example, in patients with a single
ventricle after the Fontan palliation the main mechanism of heart
Figure 2. Receiver-operating characteristic (ROC) curves for identifying patients with severely limited cardiopulmonary exercise
capacity.
doi:10.1371/journal.pone.0033795.g002
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limitations of NT-proBNP as a biomarker for heart failure in
adults with congenital heart disease.
A limitation of this study is its cross-sectional design. To allow
predictions about the prognostic value of elevated ADMA levels a
longitudinal study is needed. This would be of great interest since
previous studies suggest that NT-proBNP is not helpful in
predicting clinical course of heart failure in ACHD [4]. Therefore,
a long-term follow up study of the patients that participated in this
study is already under way.
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